Twitter LinkedIn
Return to Wellspring

Projects Sharing Researchers


Acute Megakarocytic Leukemia (AMKL) Treatment


Project TitleAcute Megakarocytic Leukemia (AMKL) Treatment
Track Code2008-077
Short Description

New approach for treating AMKL by inducing polyploidization to revert cancerous cells into normal cells

#therapeutics #cancer # smallmolecules


A unique therapeutic approach for acute megakaryocytic leukemia (AMKL) has been developed at Northwestern University. AMKL is an aggressive form of blood cancer for which there are few promising drug options. Based upon their identification of a unique feature of AMKL cells, Northwestern scientists developed an innovative treatment strategy. Cancerous megakaryocytic cells in AMKL sidestep a normal differentiation process called polyploidization. The screening method Prof. Crispino and colleagues designed may be used to search for compounds that would induce this process and render the cancerous cells normal. They believe this approach to chemotherapy may be less toxic to patients and would produce fewer side effects than standard chemotherapies, which eliminate both cancerous and healthy cells.

TagsTHERAPEUTICS: cancer, THERAPEUTICS: small molecule
Posted DateMay 5, 2015 1:04 PM


John Crispino*

Qiang Wen

Zan Huang

Robert Gould

Andrew Stern


  • Treatment of AMKL and other megakaryopoetic diseases
  • Research reagents for study of megakaryocytes


  • Low chance of side-effects
  • Applicable to various megakaryopoetic disorders


IP Status

Issued US patent 8,993,071

Contact Information

Michael Moore, PhD

Invention Manager

(p) 847.491.4645